{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/vestibular-neuronitis/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"06a83e39-ba88-5cb5-872a-7b5e56e06a3c","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 7ac63edc-58e8-44e1-a1e5-70d9642b05f0 --><h2>Changes</h2><!-- end field 7ac63edc-58e8-44e1-a1e5-70d9642b05f0 -->","summary":null,"htmlStringContent":"<!-- begin item 182c8555-c0f8-42af-ac46-82daf252911b --><!-- begin field 6e061064-9f13-4983-ae53-9320f0c6dd63 --><p><strong>November 2017</strong> — reviewed. A literature search was conducted in August 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of this topic. Minor changes have been made to the sections on diagnosis and symptomatic treatment and a link to patient information has been added. The prescribing information section now includes more detailed information on dosage, contraindications, cautions, adverse effects, and interactions for the recommended drugs.</p><!-- end field 6e061064-9f13-4983-ae53-9320f0c6dd63 --><!-- end item 182c8555-c0f8-42af-ac46-82daf252911b -->","topic":{"id":"4161326f-3a9d-549b-a377-dc2f2a6f809a","topicId":"d53e1081-ae57-4dcc-8ee8-14e6be6fb3d6","topicName":"Vestibular neuronitis","slug":"vestibular-neuronitis","lastRevised":"Last revised in November 2017","chapters":[{"id":"1371e2f5-4cd3-5674-aae3-79470e21b62b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"cb3f7155-69a7-5a7f-b8c1-2a1a113f0070","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a45dcd81-fea0-598a-ba01-782b350ffabd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"06a83e39-ba88-5cb5-872a-7b5e56e06a3c","slug":"changes","fullItemName":"Changes"},{"id":"c9683178-6f5b-5445-a2d4-02d27c379f4b","slug":"update","fullItemName":"Update"}]},{"id":"a9baddc3-bb87-54e7-b6bf-fb890ce8d86d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"65c0b807-ad55-5cb6-8ac0-1beaf353fd29","slug":"goals","fullItemName":"Goals"},{"id":"c577b7a6-4f03-5974-a443-32000f43d67c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"300cd325-7e03-5d62-afb6-803945166705","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4e3892d6-0403-52e9-a509-fc65bd12340b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"c67ef3c1-dad6-5fbc-9fc2-1f9ef2f8fcef","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e83fe4f4-878e-59eb-a20b-f35218ed5023","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d4fd633a-c05b-5b41-9dc2-d862bc4286b5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8ab4ebcd-03e4-5892-9e29-aabb20cb8f45","slug":"definition","fullItemName":"Definition"},{"id":"552f3d90-3666-593b-b806-28115dcd8f3b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1966c14e-e128-5b21-bbce-6b9d4f48924d","slug":"complications","fullItemName":"Complications"},{"id":"f30ad763-2643-586e-9d19-cffd5f45d021","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"adbff71b-d255-5959-953d-3b2788094c8b","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"081f5ce9-172b-5beb-9ace-bbe7a9e86705","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ba7e323e-e894-5821-9164-ea7cd07a38b4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"7c05a5c3-6c86-5daa-aed5-df8280f3723a","fullItemName":"Management","slug":"management","subChapters":[{"id":"f6abc1bb-cef0-5ec3-abe6-ca99c3f79fa7","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"ac81d77a-e9b5-5b14-9a42-63c17716a3f4","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"1ae90a52-6113-534c-8cf7-46d78bb039a3","slug":"cinnarizine","fullItemName":"Cinnarizine"},{"id":"354fa7f8-799b-53ab-900a-b4083df52ec8","slug":"cyclizine","fullItemName":"Cyclizine"},{"id":"4df87a4b-4d5c-56b0-b766-c143a60b38e8","slug":"prochlorperazine","fullItemName":"Prochlorperazine"},{"id":"ac9da5a7-a091-516f-a6b1-03ed2d2f7156","slug":"promethazine-teoclate","fullItemName":"Promethazine teoclate"}]},{"id":"9f00019c-78be-54da-b9cb-69c6c04c5063","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c39d54c3-45ec-52b9-9dd2-efc3f3caa200","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d04e0140-1610-5826-9319-63f03c35c2d1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"763af5f7-891e-5c76-9970-ae093e35ae7b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d0088dd9-7199-53a5-a4d0-e4299a54c061","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c9ae115f-4e3a-5af0-870e-16c967836515","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"27450791-3a41-5a8d-951b-efe744ca7944","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"49115179-8551-5f4b-9d71-06a60c3445da","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a45dcd81-fea0-598a-ba01-782b350ffabd","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"15d0c767-204d-54ff-bc27-02c652226ff5","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 4926dfa9-21a2-4ac6-a52c-a82a00bf4ddd --><h3>Previous changes</h3><!-- end field 4926dfa9-21a2-4ac6-a52c-a82a00bf4ddd -->","summary":null,"htmlStringContent":"<!-- begin item 430d6f65-7642-4e27-919f-a82a00bf4a14 --><!-- begin field bf683034-e2bb-486b-99ec-a82a00bf4ddd --><p><strong>December 2016 </strong>— minor update. The contraindications and adverse effects of prochlorperazine have been updated in line with the manufacturer's Summary of Product Characteristics.</p><p><strong>July 2013 </strong>— minor update. Links to the DVLA website have been updated.</p><p><strong>November 2010 to February 2011 </strong>— this is a new CKS topic. The evidence-base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field bf683034-e2bb-486b-99ec-a82a00bf4ddd --><!-- end item 430d6f65-7642-4e27-919f-a82a00bf4a14 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}